Rotavirus vaccination in the US: a systematic review of vaccination coverage and completion

Hum Vaccin Immunother. 2021 Mar 4;17(3):872-879. doi: 10.1080/21645515.2020.1794440. Epub 2020 Aug 26.

Abstract

A systematic literature review of Medline and Embase databases was conducted to describe rotavirus (RV) vaccine coverage for a complete series, timing of receipt of all doses in the series, and predictors of RV vaccination coverage in the US for two licensed RV vaccines (RV1, RV5). Nine publications were included in the review. RV vaccination coverage rates of under 80% suggest RV vaccines are underutilized relative to the Healthy People 2020 target and other childhood vaccines. About 50-90% of children initiating RV vaccination complete the series and coverage for a complete series is lower for black and Hispanic children (vs. whites), uninsured or Medicaid insured (vs. privately insured), and for foreign-born (vs. US-born) children. Series completion is significantly greater in children receiving DTaP, RV1 (vs. RV5), and for those receiving routine care from a pediatrician. There is a need to design and implement better RV immunization strategies for US children.

Keywords: Rotavirus vaccines; United States; completion; compliance; coverage.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Child
  • Humans
  • Infant
  • Rotavirus Infections* / epidemiology
  • Rotavirus Infections* / prevention & control
  • Rotavirus Vaccines*
  • Rotavirus*
  • United States
  • Vaccination
  • Vaccination Coverage
  • Vaccines, Attenuated

Substances

  • Rotavirus Vaccines
  • Vaccines, Attenuated

Grants and funding

This work was supported by GlaxoSmithKline Biologicals SA (GSK study identifier: HO-17-19030) which was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript.